New cell therapy aims to mop up lingering lymphoma
NCT ID NCT07006012
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests a new cell therapy called RGL-305 in 12 lymphoma patients who still have traces of cancer after standard treatment. The therapy is given through an IV over several cycles. The main goal is to check if it is safe and how the cells behave in the body, not yet to prove it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- RGL-305 (a cell therapy given intravenously)
- What this could lead to
- If it works, this could point toward a new way to eliminate remaining cancer cells in lymphoma patients who still have minimal disease after standard treatment.
- What could go wrong
- This is a very early, small study with only 12 participants, so results may not apply broadly. The main goal is safety, not yet proof of effectiveness, and cell therapies can cause serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA PATIENTS WITH COMPLETE RESPONSE (CR) OR PARTIAL RESPONSE (PR) AFTER STANDARD TREATMENT HAD A POSITIVE MINIMAL RESIDUAL LESION (MRD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 201200, China